ATEC

Business Context and Reporting Period

Company: Alphatec Holdings, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Industry: Medical Technology (Spine Disorders)
Overview: Alphatec designs, develops, manufactures, and markets products for the surgical treatment of spine disorders, with a strategic focus on the "aging spine" market. The company operates a state-of-the-art in-house manufacturing facility in Carlsbad, California, and sells products globally, including in the U.S., Japan, Europe, and South America. Products include spinal fixation systems, spacers, plates, and biologics.

Key Financial Metrics (Year Ended Dec 31, 2009)

Adjusted EBITDA: $15.0 million (Non-GAAP measure reconciled from Net Loss).

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 30.4% to $132.2 million, driven by a 28.3% increase in U.S. sales (new Illico product line and existing portfolio) and a 32.7% increase in Asia sales. European sales grew 92.9% due to new distributor additions.
• Profitability Improvement: Operating loss narrowed significantly from $27.8 million in 2008 to $9.6 million in 2009. This improvement was primarily due to the absence of a $11.0 million one-time litigation settlement expense recorded in 2008.
• Expense Trends:
  • In-Process R&D (IPR&D): Increased 132.1% to $6.4 million due to milestone payments for licensed technologies (OsseoScrew, stand-alone spacers, and spinal stenosis devices).
  • Sales & Marketing: Increased 21.4% to $51.5 million, largely due to higher commissions from increased sales volume.
  • Interest Expense: Increased 85.1% to $3.5 million due to larger average outstanding debt balances under the 2008 credit facility.
• Balance Sheet: Cash decreased by $8.2 million due to operating cash outflows and significant investing activities ($12.7 million used for surgical instruments and equipment).

Guidance, Outlook, Risks, and Unusual Items

Strategic Acquisition

On December 17, 2009, the company entered into a definitive agreement to acquire Scient'x Groupe S.A.S., a French medical device company. The transaction is an all-stock deal involving the issuance of 24,000,000 shares of Alphatec common stock (approx. 45.7% of pre-transaction voting shares). The deal is subject to shareholder approval and expected to close in Q1 2010.

Liquidity and Debt Covenants

The company operates under a $30 million credit facility ($15M term loan, $15M line of credit) with Silicon Valley Bank and Oxford Finance. The facility requires compliance with minimum revenue and Adjusted EBITDA covenants. Management believes the 2010 operating plan will meet these covenants, but failure to achieve growth targets could result in a default and acceleration of debt.

Regulatory and Legal Risks

• FDA Inspections: The FDA conducted inspections in November 2009 and January 2010, issuing Form 483s citing non-compliance items. The company has submitted responses, but follow-up inspections are ongoing.
• Litigation: A new complaint was filed on February 12, 2010, by Cross Medical Products, LLC, alleging unpaid royalties on polyaxial pedicle screw components. The company believes the allegations are without merit.
• Scient'x Legal Review: Scient'x was previously named in a qui tam complaint regarding consulting payments to surgeons. While dismissed without prejudice, the DOJ continues to review the allegations.

Unusual Items

Deferred Revenue: Due to extended payment terms with new European distributors and a U.S. distributor with limited credit history, the company deferred revenue recognition until cash is received or payments are due. This impacted the timing of revenue recognition in 2009.

Investor Verification Checklist

• Acquisition Dilution: Verify the impact of the 24 million share issuance for the Scient'x acquisition on earnings per share and ownership structure.
• Debt Covenant Compliance: Monitor Q1 and Q2 2010 results to ensure the company meets the minimum revenue and Adjusted EBITDA covenants required by its credit facility.
• FDA Compliance Status: Confirm the resolution of the Form 483 citations from the November 2009 and January 2010 inspections to ensure no manufacturing restrictions are imposed.
• Scient'x Integration: Assess the timeline and costs associated with integrating Scient'x operations and the potential for additional transaction-related charges.
• Legal Exposure: Track the progress of the Cross Medical Products, LLC lawsuit regarding royalty payments on polyaxial screws.